Stock MYGN MYRIAD GENETICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
25.47 USD +0.87% Intraday chart for Myriad Genetics, Inc. +32.52% +33.07%
May. 08 Sector Update: Health Care Stocks Softer Late Afternoon MT
May. 08 Myriad Genetics Shares Rise After Reporting Narrower Q1 Adjusted Loss, Higher Revenue MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Softer Late Afternoon
MT
Myriad Genetics Shares Rise After Reporting Narrower Q1 Adjusted Loss, Higher Revenue
MT
Eurobio Scientific: agreement with Myriad Genetics
CF
Eurobio Scientific to Buy Gene Expression Test for Breast Cancer
MT
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q1 Revenue $202.2M, vs. Street Est of $193.3M
MT
(MYGN) MYRIAD GENETICS Sees Fiscal Year 2024 EPS Range $0.00 - $0.05
MT
(MYGN) MYRIAD GENETICS Sees Fiscal Year 2024 Revenue Range $820M - $840M
MT
Myriad: Q1 Earnings Snapshot
AQ
Myriad Genetics to Seek Acquisitions
CI
Transcript : Myriad Genetics, Inc., Q1 2024 Earnings Call, May 07, 2024
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
GL
Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024
CI
Myriad Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
GL
Eurobio Scientific Société anonyme signed a definitive agreement to acquire EndoPredict business of Myriad Genetics, Inc for $10 million.
CI
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
GL
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel Prenatal Screen
AQ
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
GL
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
GL
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MYGN Stock
  4. News Myriad Genetics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW